Close Menu

This story has been updated with information from a conference call with NeoGenomics executives discussing the financial results.

NEW YORK – NeoGenomics Tuesday reported a 14 percent year-over-year decline in its second quarter revenues due to fallout from the COVID-19 pandemic.

For the three months ended June 30, total revenues reached $87.0 million, down from $101.7 million in Q2 2019, and slightly beating analysts' average estimate of $86.6 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.